534 related articles for article (PubMed ID: 28925899)
1. A Review on the Effects of Androgen Deprivation Therapy (ADT) on Bone Health Status in Men with Prostate Cancer.
Mohamad NV; Soelaiman IN; Chin KY
Endocr Metab Immune Disord Drug Targets; 2017 Nov; 17(4):276-284. PubMed ID: 28925899
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
3. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of androgen deprivation therapy in prostate cancer patients.
Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
[TBL] [Abstract][Full Text] [Related]
6. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
7. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
8. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial.
Uth J; Hornstrup T; Christensen JF; Christensen KB; Jørgensen NR; Schmidt JF; Brasso K; Jakobsen MD; Sundstrup E; Andersen LL; Rørth M; Midtgaard J; Krustrup P; Helge EW
Osteoporos Int; 2016 Apr; 27(4):1507-1518. PubMed ID: 26572756
[TBL] [Abstract][Full Text] [Related]
10. Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update.
Owen PJ; Daly RM; Livingston PM; Fraser SF
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):137-145. PubMed ID: 28117386
[TBL] [Abstract][Full Text] [Related]
11. Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
Bergamini M; Dalla Volta A; Palumbo C; Zamboni S; Triggiani L; Zamparini M; Laganà M; Rinaudo L; Di Meo N; Caramella I; Bresciani R; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Mazziotti G; Berruti A
Elife; 2024 Apr; 13():. PubMed ID: 38656229
[TBL] [Abstract][Full Text] [Related]
12. An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer.
Merseburger AS; Hupe MC
Adv Ther; 2016 Jul; 33(7):1072-93. PubMed ID: 27246172
[TBL] [Abstract][Full Text] [Related]
13. A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol.
Langley RE; Kynaston HG; Alhasso AA; Duong T; Paez EM; Jovic G; Scrase CD; Robertson A; Cafferty F; Welland A; Carpenter R; Honeyfield L; Abel RL; Stone M; Parmar MK; Abel PD
Eur Urol; 2016 Jun; 69(6):1016-25. PubMed ID: 26707868
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of a multi-component exercise programme and nutritional supplementation on musculoskeletal health in men treated with androgen deprivation therapy for prostate cancer (IMPACT): study protocol of a randomised controlled trial.
Owen PJ; Daly RM; Livingston PM; Mundell NL; Dalla Via J; Millar JL; Fraser SF
Trials; 2017 Oct; 18(1):451. PubMed ID: 28974267
[TBL] [Abstract][Full Text] [Related]
15. The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients.
Khriguian J; Tsui JMG; Vaughan R; Kucharczyk MJ; Nabid A; Bettahar R; Vincent L; Martin AG; Jolicoeur M; Yassa M; Barkati M; Igidbashian L; Bahoric B; Archambault R; Villeneuve H; Mohiuddin M; Niazi T
J Urol; 2021 Jun; 205(6):1648-1654. PubMed ID: 33577365
[TBL] [Abstract][Full Text] [Related]
16. Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.
Schulman C; Irani J; Aapro M
BJU Int; 2012 Jun; 109 Suppl 6():13-21. PubMed ID: 22672121
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer, osteoporosis and fracture risk.
Allain TJ
Gerontology; 2006; 52(2):107-10. PubMed ID: 16508318
[TBL] [Abstract][Full Text] [Related]
18. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.
Grossmann M; Hamilton EJ; Gilfillan C; Bolton D; Joon DL; Zajac JD
Med J Aust; 2011 Mar; 194(6):301-6. PubMed ID: 21426285
[TBL] [Abstract][Full Text] [Related]
19. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
20. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
Dhanapal V; Reeves DJ
J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
